

Biosimilar Interleukins Global Market 2024 To Reach \$20.79 Billion By 2028 At Rate Of 40.0%

*The Business Research Company's
Biosimilar Interleukins Global Market
2024 To Reach \$20.79 Billion By 2028 At
Rate Of 40.0%*

LONDON, GREATER LONDON, UK,
August 7, 2024 /EINPresswire.com/ --
The biosimilar interleukins market has
experienced robust growth in recent
years, expanding from \$3.9 billion in

2023 to \$5.41 billion in 2024 at a compound annual growth rate (CAGR) of 39.0%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, and increasing patient demand for biosimilars.



The Business
Research Company

Biosimilar Interleukins Global Market Report 2024
-Market Size, Trends, And Global Forecast 2024-2033



The biosimilar interleukins market is projected to continue its strong growth, reaching \$20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%."

*The Business Research
Company*

Strong Future Growth Anticipated

The biosimilar interleukins market is projected to continue its strong growth, reaching \$20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to the growing patient population, increased access to healthcare, growing demand for personalized medicine, and growing demand for minimally invasive procedures.

Explore Comprehensive Insights Into The Global Biosimilar Interleukins Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample_request?id=3433&type=smp

Growth Driver Of The Biosimilar Interleukins Market

The rise in the prevalence of arthritis is expected to propel the growth of the biosimilar interleukins market. Arthritis is a term employed to characterize discomfort or illness affecting the joints, involving the inflammation or enlargement of one or multiple joints. Biosimilars, which encompass interleukins, find utility in the treatment of diverse inflammatory and autoimmune conditions like rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis,

psoriatic arthritis, and ankylosing spondylitis.

Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:

<https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report>

Major Players And Market Trends

Key players in the biosimilar interleukins market include Mabpharm Limited, Gedeon Richter PLC, Bio-Thera Solutions Ltd., Sorrento Therapeutics, Sunshine Guojian Pharmaceutical.

Major companies operating in the biosimilar interleukins market are innovating new products such as Tofidence (tocilizumab-bavi) to increase their profitability in the market. Tofidence is a monoclonal antibody that targets and attaches to interleukin-6 receptors, employed in the treatment of various inflammatory autoimmune disorders.

Segments:

- 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
- 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
- 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Geographical Insights: North America Leading The Market

North America was the largest region in the biosimilar interleukins market in 2023. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Biosimilar Interleukins Market Definition

Biosimilar interleukins are defined as biosimilars produced by the body's leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment.

Biosimilar Interleukins Global Market Report 2024 from [The Business Research Company](#) covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Biosimilar Interleukins Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on biosimilar interleukins market size, biosimilar interleukins market drivers and trends, biosimilar interleukins market major players,

biosimilar interleukins competitors' revenues, biosimilar interleukins market positioning, and biosimilar interleukins market growth across geographies. The biosimilar interleukins market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Generic Pharmaceuticals Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report>

Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report>

Oncology Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report>

About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/733610353>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.